Company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3
Curis strengthens executive team with appointment of industry veteran Jonathan Zung, Ph.D. as Chief Development Officer
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.